Hyderabad, May 20 (SocialNews.XYZ) Bharat Biotech on Thursday announced the quick ramp up of additional manufacturing capacities for Covid-19 vaccine Covaxin by an additional 200 million.
The manufacturing capacities for India's first indigenous Covid vaccine have been ramped up at Chiron Behring Vaccines, a wholly-owned subsidiary of Bharat Biotech at Ankleshwar, Gujarat.
The company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety, Hyderabad-based Bharat Biotech said in a statement.
The product availability at Ankleshwar is expected to commence from fourth quarter of 2021.
Bharat Biotech had already deployed multiple production lines at its Hyderabad and Bengaluru campuses, adding Chiron Behring to this line-up of high-containment BSL rated GMP facilities that are required to manufacture Covaxin.
This effectively takes the volumes up to about one billion doses per annum, with its own established campuses specialised for manufacturing inactivated viral vaccines under the highest levels of biosafety, the vaccine maker added.
Source: IANS
Gopi Adusumilli is a Programmer. He is the editor of SocialNews.XYZ and President of AGK Fire Inc.
He enjoys designing websites, developing mobile applications and publishing news articles on current events from various authenticated news sources.
When it comes to writing he likes to write about current world politics and Indian Movies. His future plans include developing SocialNews.XYZ into a News website that has no bias or judgment towards any.
He can be reached at gopi@socialnews.xyz
This website uses cookies.
